8-K: Dare Bioscience Faces Nasdaq Delisting Threat

Dare Bioscience has received a notice from Nasdaq indicating its common stock is subject to delisting due to non-compliance with minimum stockholders' equity requirements.

Summary

• Dare Bioscience, Inc. received a notification from Nasdaq on July 13, 2026, stating that the company is not in compliance with Nasdaq Listing Rule 5550(b).
• This non-compliance is due to stockholders' equity being less than $2.5 million as reported in the Form 10-Q for the period ended March 31, 2026.
• The company also did not meet the alternative requirements of $35 million in market value of listed securities or $500,000 in net income from continuing operations as of July 13, 2026.
• Consequently, the company's common stock is subject to delisting from Nasdaq.
• Dare Bioscience intends to request a hearing before the Nasdaq Hearing Panel to address this deficiency.
• A hearing request will temporarily stay the suspension and delisting pending the Panel's decision and any granted extension period.
• There is no guarantee that the Panel will grant an extension or that the company will regain compliance within any extended period.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development due to the immediate threat of delisting from Nasdaq, which poses substantial risks to liquidity and investor confidence.

Negatives

• The company is at risk of delisting from the Nasdaq Capital Market due to failing to meet minimum stockholders' equity requirements.
• Stockholders' equity was below the $2.5 million threshold as of March 31, 2026.
• The company did not meet alternative Nasdaq listing criteria for market value or net income as of July 13, 2026.

Risks

• The primary risk is the delisting of the company's common stock from the Nasdaq Capital Market, which could significantly impact liquidity and investor confidence.
• Failure to regain compliance with Nasdaq Listing Rule 5550(b) within any granted extension period.
• Uncertainty regarding the Nasdaq Hearing Panel's decision on the request for a hearing and potential extension.
• Potential negative impact on the company's ability to raise capital or attract future investment if delisted.

Future Outlook

The company intends to request a hearing with the Nasdaq Hearing Panel to address the non-compliance with listing rules. There is uncertainty regarding the outcome of this hearing and whether the company will be able to regain compliance and maintain its listing on Nasdaq.

Management Comments

• The Company intends to timely request a hearing before the Panel.
• There can be no assurance that the Panel will grant the Companys request for an extension to evidence compliance with the Rule, or if any such extension period is granted, that the Company will regain compliance with the Rule within such extension period, or that the Company will be successful in otherwise maintaining the listing of its common stock on Nasdaq.

Industry Context

StockSavvy.ai notes that Nasdaq delisting notices are a critical event for small-cap and micro-cap biotechnology companies, often signaling financial distress or challenges in meeting exchange requirements. This situation can severely impact a company's ability to access capital markets and can lead to increased volatility.

Stakeholder Impact

• Shareholders: Potential for decreased stock liquidity, increased volatility, and difficulty in trading shares if delisted. Reduced investor confidence.
• Creditors: May view the delisting risk as an indicator of financial instability, potentially impacting credit terms.
• Employees: Uncertainty about the company's future and potential impact on job security.
• Potential Investors: May be deterred from investing due to the increased risk and reduced liquidity associated with a non-exchange-listed stock.

Next Steps

• Request a hearing before the Nasdaq Hearing Panel.
• Present evidence of compliance or a plan to regain compliance to the Panel.
• Await the Panel's decision regarding the company's listing status.

Key Dates

Recommendation

While the delisting notice is a significant negative, the company's intent to request a hearing provides a potential path to maintaining its listing. A 'hold' recommendation reflects the uncertainty; investors should await the outcome of the Nasdaq hearing before making further decisions. Significant risk remains if compliance is not achieved.

Keywords

Nasdaq delisting, Listing Rule 5550(b), Stockholders' equity, Dare Bioscience, SEC filing, Form 8-K, Capital Market, Compliance